Kalgutkar AS - Search Results

1

Oxidative metabolism of a quinoxaline derivative by xanthine oxidase in rodent plasma.

Sharma R, Eng H, Walker GS, Barreiro G, Stepan AF, McClure KF, Wolford A, Bonin PD, Cornelius P, Kalgutkar AS. Sharma R, et al. Among authors: kalgutkar as. Chem Res Toxicol. 2011 Dec 19;24(12):2207-16. doi: 10.1021/tx200329k. Epub 2011 Oct 4. Chem Res Toxicol. 2011. PMID: 21939274

2

Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors.

Kalgutkar AS, Dalvie DK, Castagnoli N Jr, Taylor TJ. Kalgutkar AS, et al. Chem Res Toxicol. 2001 Sep;14(9):1139-62. doi: 10.1021/tx010073b. Chem Res Toxicol. 2001. PMID: 11559028 Review. No abstract available.

3

Biotransformation reactions of five-membered aromatic heterocyclic rings.

Dalvie DK, Kalgutkar AS, Khojasteh-Bakht SC, Obach RS, O'Donnell JP. Dalvie DK, et al. Among authors: kalgutkar as. Chem Res Toxicol. 2002 Mar;15(3):269-99. doi: 10.1021/tx015574b. Chem Res Toxicol. 2002. PMID: 11896674 Review. No abstract available.

4

A semiquantitative method for the determination of reactive metabolite conjugate levels in vitro utilizing liquid chromatography-tandem mass spectrometry and novel quaternary ammonium glutathione analogues.

Soglia JR, Contillo LG, Kalgutkar AS, Zhao S, Hop CE, Boyd JG, Cole MJ. Soglia JR, et al. Among authors: kalgutkar as. Chem Res Toxicol. 2006 Mar;19(3):480-90. doi: 10.1021/tx050303c. Chem Res Toxicol. 2006. PMID: 16544956

5

Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: identification of candidates for clinical development.

McClure KF, Letavic MA, Kalgutkar AS, Gabel CA, Audoly L, Barberia JT, Braganza JF, Carter D, Carty TJ, Cortina SR, Dombroski MA, Donahue KM, Elliott NC, Gibbons CP, Jordan CK, Kuperman AV, Labasi JM, Laliberte RE, McCoy JM, Naiman BM, Nelson KL, Nguyen HT, Peese KM, Sweeney FJ, Taylor TJ, Trebino CE, Abramov YA, Laird ER, Volberg WA, Zhou J, Bach J, Lombardo F. McClure KF, et al. Among authors: kalgutkar as. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4339-44. doi: 10.1016/j.bmcl.2006.05.056. Epub 2006 Jun 12. Bioorg Med Chem Lett. 2006. PMID: 16759861

6

Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.

Kalgutkar AS, Hatch HL, Kosea F, Nguyen HT, Choo EF, McClure KF, Taylor TJ, Henne KR, Kuperman AV, Dombroski MA, Letavic MA. Kalgutkar AS, et al. Biopharm Drug Dispos. 2006 Nov;27(8):371-86. doi: 10.1002/bdd.520. Biopharm Drug Dispos. 2006. PMID: 16944451

7

Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation.

Kalgutkar AS, Dalvie DK, Aubrecht J, Smith EB, Coffing SL, Cheung JR, Vage C, Lame ME, Chiang P, McClure KF, Maurer TS, Coelho RV Jr, Soliman VF, Schildknegt K. Kalgutkar AS, et al. Drug Metab Dispos. 2007 Jun;35(6):848-58. doi: 10.1124/dmd.106.013649. Epub 2007 Mar 7. Drug Metab Dispos. 2007. PMID: 17344339

8

Bioactivation of phencyclidine in rat and human liver microsomes and recombinant P450 2B enzymes: evidence for the formation of a novel quinone methide intermediate.

Driscoll JP, Kornecki K, Wolkowski JP, Chupak L, Kalgutkar AS, O'Donnell JP. Driscoll JP, et al. Among authors: kalgutkar as. Chem Res Toxicol. 2007 Oct;20(10):1488-97. doi: 10.1021/tx700145k. Epub 2007 Sep 25. Chem Res Toxicol. 2007. PMID: 17892269

9

NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine.

Zhao SX, Dalvie DK, Kelly JM, Soglia JR, Frederick KS, Smith EB, Obach RS, Kalgutkar AS. Zhao SX, et al. Among authors: kalgutkar as. Chem Res Toxicol. 2007 Nov;20(11):1649-57. doi: 10.1021/tx700132x. Epub 2007 Oct 2. Chem Res Toxicol. 2007. PMID: 17907785

10

A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif.

Kalgutkar AS, Driscoll J, Zhao SX, Walker GS, Shepard RM, Soglia JR, Atherton J, Yu L, Mutlib AE, Munchhof MJ, Reiter LA, Jones CS, Doty JL, Trevena KA, Shaffer CL, Ripp SL. Kalgutkar AS, et al. Chem Res Toxicol. 2007 Dec;20(12):1954-65. doi: 10.1021/tx700270r. Epub 2007 Oct 13. Chem Res Toxicol. 2007. PMID: 17935300

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

167 results

Search Page